Abstract

Tumor invasion and metastasis are the main cause of cancer mortality. CSE1L/CAS, the cellular apoptosis susceptibility protein, is the human homologue of the yeast chromosome segregation gene product, CSE1. Pathological studies show that CSE1L is highly expressed in various cancers, such as lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial carcinomas, skin cancer, colorectal cancer, lymphomas, prostate cancers, nasopharyngeal carcinomas, medulloblastomas, and glioblastomas. The CSE1L gene is located on chromosome 20q13, a region that frequently harbors amplifications that correlate with cancer aggression. Experimental studies have shown that CSE1L regulates the invasion of cancer cells in vitro and in animal metastasis models. The results of our recent studies have revealed that CSE1L is a secretory protein present in sera from cancer patients. Significantly, there is a higher prevalence of secretory CSE1L in sera of patients with metastatic cancer. Here, we discuss the potential of CSE1L as a serum marker for the diagnosis of cancer.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume3
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Cellular Apoptosis Susceptibility Protein
Blood Proteins
Neoplasms
Liver Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Chromosome Segregation
Medulloblastoma
Skin Neoplasms
Glioblastoma
Endometrial Neoplasms
Serum
Aggression
Ovarian Neoplasms
Genes
Colorectal Neoplasms
Lymphoma
Lung Neoplasms
Animal Models

Keywords

  • Cancer marker
  • CSE1L
  • Metastasis
  • Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{37587e5b1b5e43ef883112b4ef8e6225,
title = "Serum Cellular Apoptosis Susceptibility Protein for Cancer Diagnosis",
abstract = "Tumor invasion and metastasis are the main cause of cancer mortality. CSE1L/CAS, the cellular apoptosis susceptibility protein, is the human homologue of the yeast chromosome segregation gene product, CSE1. Pathological studies show that CSE1L is highly expressed in various cancers, such as lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial carcinomas, skin cancer, colorectal cancer, lymphomas, prostate cancers, nasopharyngeal carcinomas, medulloblastomas, and glioblastomas. The CSE1L gene is located on chromosome 20q13, a region that frequently harbors amplifications that correlate with cancer aggression. Experimental studies have shown that CSE1L regulates the invasion of cancer cells in vitro and in animal metastasis models. The results of our recent studies have revealed that CSE1L is a secretory protein present in sera from cancer patients. Significantly, there is a higher prevalence of secretory CSE1L in sera of patients with metastatic cancer. Here, we discuss the potential of CSE1L as a serum marker for the diagnosis of cancer.",
keywords = "Cancer marker, CSE1L, Metastasis, Serum",
author = "Tai, {Cheng Jeng} and Chang, {Chun Chao} and Shen, {Shing Chuan} and Lee, {Woan Ruoh} and Jiang, {Ming Chung}",
year = "2011",
month = "6",
doi = "10.1016/j.jecm.2011.04.003",
language = "English",
volume = "3",
pages = "104--107",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Serum Cellular Apoptosis Susceptibility Protein for Cancer Diagnosis

AU - Tai, Cheng Jeng

AU - Chang, Chun Chao

AU - Shen, Shing Chuan

AU - Lee, Woan Ruoh

AU - Jiang, Ming Chung

PY - 2011/6

Y1 - 2011/6

N2 - Tumor invasion and metastasis are the main cause of cancer mortality. CSE1L/CAS, the cellular apoptosis susceptibility protein, is the human homologue of the yeast chromosome segregation gene product, CSE1. Pathological studies show that CSE1L is highly expressed in various cancers, such as lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial carcinomas, skin cancer, colorectal cancer, lymphomas, prostate cancers, nasopharyngeal carcinomas, medulloblastomas, and glioblastomas. The CSE1L gene is located on chromosome 20q13, a region that frequently harbors amplifications that correlate with cancer aggression. Experimental studies have shown that CSE1L regulates the invasion of cancer cells in vitro and in animal metastasis models. The results of our recent studies have revealed that CSE1L is a secretory protein present in sera from cancer patients. Significantly, there is a higher prevalence of secretory CSE1L in sera of patients with metastatic cancer. Here, we discuss the potential of CSE1L as a serum marker for the diagnosis of cancer.

AB - Tumor invasion and metastasis are the main cause of cancer mortality. CSE1L/CAS, the cellular apoptosis susceptibility protein, is the human homologue of the yeast chromosome segregation gene product, CSE1. Pathological studies show that CSE1L is highly expressed in various cancers, such as lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial carcinomas, skin cancer, colorectal cancer, lymphomas, prostate cancers, nasopharyngeal carcinomas, medulloblastomas, and glioblastomas. The CSE1L gene is located on chromosome 20q13, a region that frequently harbors amplifications that correlate with cancer aggression. Experimental studies have shown that CSE1L regulates the invasion of cancer cells in vitro and in animal metastasis models. The results of our recent studies have revealed that CSE1L is a secretory protein present in sera from cancer patients. Significantly, there is a higher prevalence of secretory CSE1L in sera of patients with metastatic cancer. Here, we discuss the potential of CSE1L as a serum marker for the diagnosis of cancer.

KW - Cancer marker

KW - CSE1L

KW - Metastasis

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=79958841701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958841701&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2011.04.003

DO - 10.1016/j.jecm.2011.04.003

M3 - Article

AN - SCOPUS:79958841701

VL - 3

SP - 104

EP - 107

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -